Perinatal outcomes associated with ICP in twin pregnancies were worse than singletons: an almost 5-year retrospective cohort study

Tingting Xu1,2, Chunyan Deng1,2, Yongchi Zhan1,2, Qing Hu1,2, Guiqiong Huang1,2, Xing Wang3, Bing Guo3, Haiyan Yu1,2* and Xiaodong Wang1,2*

Abstract

**Background:** Intrahepatic cholestasis of pregnancy (ICP) is associated with an increased risk of adverse perinatal outcomes leading to high perinatal morbidity and mortality. However, few studies have examined twin pregnancies complicated by ICP. To assess the perinatal outcomes of twin pregnancies with ICP, a retrospective cohort study was conducted.

**Methods:** A total of 633 twin pregnancies and 1267 singleton pregnancies with ICP were included. In addition, a correlation study was performed on the matched total bile acid (TBA) levels from maternal serum, fetal umbilical venous blood, and amniotic fluid of 33 twin pregnancies from twin groups.

**Results:** When compared to singletons, twin pregnancies with ICP had a higher risk of cesarean section (CS) (96.4% vs. 76.1%), preterm birth (PTB) (82.6% vs. 19.7%), fetal distress (2.0% vs. 1.3%), and neonatal intensive care unit (NICU) admission (23.6% vs. 5.1%), which was significantly related to increasing TBA levels ($P < 0.05$). In twin pregnancies with TBA $\geq 100 \mu$mol/L, the incidences of CS, PTB, fetal distress, neonatal asphyxia, and meconium-stained amniotic fluid were 94.4, 100, 11.1, 5.6, and 36.1%, respectively. Furthermore, the maximum maternal TBA levels were positively correlated with TBA levels in the amniotic fluid ($r = 0.61$, $P < 0.05$) and umbilical cord blood ($r = 0.44$, $P < 0.05$), and a similar correlation was found for maternal TBA levels at delivery. TBA levels in umbilical cord blood and amniotic fluid also had a significant and positive correlation ($r = 0.52$, $P < 0.05$).

**Conclusions:** Twin pregnancies with ICP had a higher risk for adverse perinatal outcomes than singletons, which was associated with higher TBA levels. TBA can be transported through the placenta and is involved in uterus-placenta-fetal circulation.

**Keywords:** Intrahepatic cholestasis of pregnancy, Twin pregnancies, Retrospective cohort study, Perinatal outcomes

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
the prevalence of ICP in twin pregnancies is approximately 20-25% [7, 8].

ICP is associated with an increased risk of several adverse perinatal outcomes, including spontaneous and iatrogenic preterm birth (PTB), meconium-stained amniotic fluid (MSAF), fetal distress, fetal hypoxia, sudden intrauterine fetal death, respiratory distress syndrome (RDS), neonatal asphyxia, and neonatal intensive care unit (NICU) admission [1, 3, 7, 9–16], which lead to a higher risk of perinatal morbidity and mortality. Hence, active management and close antenatal monitoring are urgently needed for these pregnant women [17].

Due to an earlier presentation and higher maternal serum TBA levels, ICP appears to be more severe in twin pregnancies than in singletons [7]. However, universal or standard recommendations or professional consensus on the prenatal management of twin pregnancies with ICP are lacking. Hence, we conducted a nearly five-year retrospective cohort analysis of twin pregnancies with ICP in our hospital. We hope our findings will provide some evidence to guide the available options for their clinical treatment.

Methods
Study design overview
All included patients received routine prenatal care and were born at our hospital from Jan. 1, 2016 to Jun. 30, 2020. All data were abstracted from the electronic medical records system.

Inclusion criteria and exclusion criteria
ICP is characterized by maternal serum TBA ≥ 10 μmol/L, with or without maternal pruritus, that completely normalizes after delivery in the absence of other causes of liver dysfunction or itching [18]. In addition, ICP is diagnosed in cases of maternal pruritus with elevated serum liver transaminase enzymes and normal TBA levels (TBA < 10 μmol/L); specifically, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are twice the normal upper limits [11, 18, 19].

The gestational age of all included cases of ICP was estimated based on the first-trimester ultrasound scan. Furthermore, the chorionicity and amnionicity of twin pregnancies with ICP were detected by ultrasonography in the first trimester and confirmed by postnatal pathology.

Main outcomes
Maternal age, height, weight gain throughout the pregnancy, family history of ICP, history of ICP, in vitro fertilization and embryo transfer (IVF-ET), PTB (iatrogenic and spontaneous), gestational age at delivery, cesarean section (CS), vaginal delivery (VD), MSAF, fetal distress, stillbirth, neonatal birth weight and height, neonatal asphyxia, neonatal death, and NICU admission were included. According to Rodríguez Fernández V, et al. [20], and different degrees of MSAF (yellow, green, and thick) were employed to compare to clear amniotic fluids in our investigation.

Laboratory analysis
The matched maternal serum, umbilical venous blood, and amniotic fluid samples of 33 twin pregnancies from twin groups were collected during the cesarean section for TBA tests. The maternal serum and umbilical cord blood levels of alanine transaminase (ALT, U/L), aspartate transaminase (AST, U/L), TBA (μmol/L), total bilirubin (TBIL, μmol/L), direct bilirubin (DBIL, μmol/L), indirect bilirubin (IDIL, μmol/L), γ-glutamyltransferase (GGT, U/L), albumin (ALB, g/L), globulin (GLB, g/L), albumin/globulin (A/G), total cholesterol (TC, mmol/L), triglyceride (TG, mmol/L), high-density lipoprotein (HDL, mmol/L), low-density lipoprotein (LDL, mmol/L), alkaline phosphatase (ALP), lactate dehydrogenase (LDH, U/L), prealbumin (PA, mg/L), fasting plasma glucose (FPG, mmol/L), apolipoproteins A1 (apo A1, g/L), apolipoproteins B (apo B, g/L), homocysteine (HCY, umol/L), sodium (Na), phosphorus (P, mmol/L), magnesium (Mg, mmol/L), calcium (Ca, mmol/L), and chloride (Cl, mmol/L), and calcium (Ca, mmol/L) were detected by Siemens-advia® chemistry kits using a fully automatic biochemical analyzer (Siemens-advia® 2400, Germany) at a medical laboratory of West China Second University Hospital of Sichuan University.

Perinatal management of ICP
Regular antenatal care for ICP was performed every 2 weeks before 28 weeks and every 1 week after 28 weeks. These prenatal tests included a nonstress test (NST), antenatal ultrasound scanning, and serial biochemical surveillance to detect worsening conditions and the risks to the fetus. Usually, NST begins at the 32nd gestational week, and it was recommended once per week for mild ICP and twice per week for severe ICP. The amniotic fluid volume, umbilical artery Doppler (S/D ratio), and fetal growth and development were all assessed using serial ultrasonography. Maternal serum liver function and TBA levels were dynamically monitored using a serial biochemical examinations. Prenatal corticosteroids were indicated for pregnant women with ICP who were at risk of PTB to enhance fetal lung development, as well as intramuscular injections of vitamin K to prevent intraventricular hemorrhage (IVH) in neonates with ICP. If fetal hypoxia or adverse events were recognized, an emergency cesarean section was immediately performed.
Statistical analysis

The data were compiled and examined using the R programming language (version 3.5.0; R Foundation for Statistical Computing, Vienna, Austria). For a baseline comparison, continuous variables were analyzed with medians and interquartile ranges (IQRs), whereas categorical variables were analyzed based on numbers and percentages. The rank-sum test was used to compare the distribution of quantitative data that did not conform to the normal distribution with the T test. For continuous variables, the mean ± standard deviation (SD) was computed for each group, and relative frequencies were estimated for categorical variables using the chi-square test ($\chi^2$ test). Multiple logistic regression models were used to obtain crude and adjusted odds ratios (ORs) for ICP with 95% confidence intervals (CIs). The correlation matrix was built using the Pearson parametric correlation test. The Holm correction was used to alter the probability values of correlation matrices for various measures. To evaluate the correlation of TBA levels, Pearson correlation scatterplots were constructed. All statistical tests were performed using a two-sided test, with significant differences defined as $P < 0.05$.

Results

A total of 633 twin pregnancies and 1267 singleton pregnancies with ICP were studied. The composition of twins includes 2 monochorionic monoamniotic (MCMA), 136 monochorionic diamniotic (MCDA), and 495 dichorionic diamniotic (DCDA) twin pregnancies. A significant difference was found in weight gain throughout pregnancy (12 vs. 15 kg), the incidence of primiparity (67.6% vs. 84.2%), ICP in a previous pregnancy (1.3% vs. 6.5%), IVF-ET (6.7% vs. 58.6%), and clinical symptoms (56.6% vs. 59.2%) between singleton and twin pregnancies with ICP ($P < 0.05$). Similarly, gestational weeks at delivery (37.44 ± 1.68 vs. 35.07 ± 1.71) also significantly differed between these two groups (Table 1).

The incidences of CS (96.4% vs. 76.1%), PTB (82.6% vs. 19.7%), fetal distress (2.0% vs. 1.3%) and NICU admission (23.6% vs. 5.1%) significantly differed between twin pregnancies and singleton pregnancies with ICP ($P < 0.05$). The mean neonatal birth weight was significantly lower in twins with ICP than in singleton pregnancies with ICP (2248.28 ± 416.20 vs. 3043.69 ± 509.10 g, respectively, $P < 0.05$), while the mean neonatal birth height was significantly lower in twins than in singleton pregnancies with ICP. The mean gestational age was significantly earlier for twins than for singleton pregnancies (35.07 ± 1.71 vs. 37.44 ± 1.68 weeks, respectively, $P < 0.05$). Subjects who had PTB were divided into three categories (< 37 weeks, < 34 weeks, < 32 weeks) according to gestational age. Most of the fetuses of twin pregnancies with ICP (82.6%, 1046/1266) were born before 37 weeks. (Table 2).

In total, 618 twin pregnancies among the 633 twin pregnancies with ICP has a TBA $\geq 10 \mu$mol/L. The maximum TBA level could determine the severity of ICP [8, 21]. To undertake subgroup analyses, these pregnant women were stratified into three categories based on the maximum level of TBA throughout the pregnancy: $10 \leq$ TBA $< 40 \mu$mol/L, $40 \leq$ TBA $< 100 \mu$mol/L, and TBA $\geq 100 \mu$mol/L [22, 23]. Significant differences were found in the risk of CS, PTB, stillbirth, fetal distress, neonatal asphyxia, birth height, birth weight, and gestational age between these three groups ($P < 0.05$). The incidences of CS, PTB, stillbirth, fetal distress, neonatal asphyxia,

| Group                              | Singleton       | Twin            | P       |
|------------------------------------|----------------|-----------------|---------|
| N                                  | 1267           | 633             |         |
| Age [years], mean (IQR)            | 30 (28, 34)    | 31 (28, 34)     | 0.51    |
| Height [cm], mean (IQR)            | 160 (156, 162) | 160 (156, 163)  | 0.66    |
| Weight gain in pregnancy [kg], mean (IQR) | 12 (10, 15)  | 15 (11, 18)     | < 0.05  |
| Gravidity, mean (IQR)              | 2 (1, 3)       | 2 (1, 3)        | < 0.05  |
| Parity, mean (IQR)                 | 1 (1, 2)       | 1 (0, 1)        | < 0.05  |
| Primiparous, n (%)                 | 856 (67.6)     | 533 (84.2)      | < 0.05  |
| ICP in previous pregnancy, n (%)   | 16 (1.3)       | 41 (6.5)        | < 0.05  |
| Family history of ICP, n (%)       | 0 (0.0)        | 0 (0.0)         | NaN     |
| IVF-ET, n (%)                      | 85 (6.7)       | 371 (58.6)      | < 0.05  |
| Clinical symptoms, n (%)           | 716 (56.6)     | 375 (59.2)      | < 0.05  |
| Gestational weeks at time of diagnosis [week], mean ± SD | 16.80 ± 8.08 | 17.40 ± 7.72   | 0.13    |
| Gestational weeks at delivery [week], mean ± SD | 37.44 ± 1.68 | 35.07 ± 1.71   | < 0.05  |

IQR Inter quartile range, IVF-ET In vitro fertilization-embryo transfer, ICP Intrahepatic cholestasis of pregnancy, Clinical symptoms including pruritus, itch, jaundice, anorexia, etc.
Table 2 The perinatal outcomes of twin and singleton pregnancies with ICP

| Obstetric outcomes          | singleton | twins | OR(95%CI) | P     | Adjusted OR(95%CI) | Adjusted P |
|----------------------------|----------|-------|-----------|-------|--------------------|------------|
| CS, n (%)                  | 1267     | 633   |           |       |                    |            |
| VD, n (%)                  | 964 (76.1) | 610 (96.4) | 8.34 (8.02, 8.66) | < 0.05 | 7.36 (7.03, 7.69) | < 0.05*    |
| MSAF, n (%)                | 303 (23.9) | 23 (3.6) | 0.12 (0.02, 0.441) | < 0.05 | 0.14 (0.019, 0.47) | < 0.05*    |

| Neonatal outcomes          | 1267     | 1266  |           |       |                    |            |
|----------------------------|----------|-------|-----------|-------|--------------------|------------|
| Gestational age [weeks]    | 37.44 ± 1.68 | 35.07 ± 1.71 | –       | < 0.05 | –                  | < 0.05*    |
| Preterm birth < 37 weeks (%) | 250 (19.7) | 1046 (82.6) | 0.23 (0.38, 0.84) | < 0.05 | 0.15 (0.49, 0.79) | < 0.05*    |
| Preterm birth < 34 weeks (%) | 38 (3.0)   | 186 (14.7)   | 0.18 (0.18, 0.54) | < 0.05 | 0.15 (0.23, 0.53) | < 0.05*    |
| Preterm birth < 32 weeks (%) | 13 (1.0)    | 55 (4.3)     | 0.05 (0.15, 0.25) | < 0.05 | 0.04 (0.17, 0.26) | < 0.05*    |
| Birth height (cm), (mean ± SD) | 48.53 ± 2.44 | 45.18 ± 2.70 | –       | < 0.05 | –                  | < 0.05*    |
| Birth weight (g), (mean ± SD) | 3043.69 ± 509.10 | 2248.28 ± 416.20 | –       | < 0.05 | –                  | < 0.05*    |
| Neonatal asphyxia, n (%)   | 15 (1.0)   | 19 (1.5)     | 1.48 (0.77, 2.19) | 0.28  | 0.53 (0.32, 1.38) | 0.15       |
| Fetal distress, n (%)      | 17 (1.3)   | 25 (2.0)     | 1.49 (0.87, 2.11) | 0.21  | 0.30 (0.44, 1.05) | < 0.05*    |
| Stillbirth, n (%)          | 0 (0.0)    | 5 (0.4)      | 0.99       | 0.99  | 0.99               |            |
| Neonatal death, n (%)      | 1 (0.1)    | 0 (0.0)      | 0.99       | 0.98  | 0.98               |            |
| NICU, n (%)                | 65 (5.1)   | 297 (23.6)   | 5.70 (5.42, 6.0) | < 0.05 | 1.9 (1.53, 2.27) | < 0.05*    |

ICP Intrahepatic cholestasis of pregnancy, TBA Total bile acid, CS Cesarean section, VD Vaginal delivery, PTB Preterm birth, NICU Neonatal Intensive Care Unit, MSAF Meconium-stained amniotic fluid

and MSAF increased as TBA concentration increased. In twin pregnancies with TBA ≥100 μmol/L, the incidences of CS, PTB, fetal distress, neonatal asphyxia, and MSAF were 94.4, 100, 11.1, 5.6, and 36.1%, respectively. All fetuses of twin pregnancies with TBA ≥100 μmol/L were born before 36 weeks, with median gestational ages of 36 (IQR 34 to 36 weeks), 35 (IQR 34 to 36 weeks), and 34 (IQR 33 to 35 weeks) among these three groups (P < 0.05). The percentage of low birth weight in twin pregnancies with TBA ≥100 μmol/L was 94.4. (Table 3).

The dynamic fluctuation of TBA-max, TBA-mean, and TBA-min during the entire pregnancy and 5 weeks post-partum at different categories of TBA levels is depicted in Fig. 1. Figure 1-A shows the dynamic fluctuation of twin pregnancies with 10 ≤ TBA < 40 μmol/L, Fig. 1-B shows twin pregnancies with 40 ≤ TBA < 100 μmol/L, Fig. 1-C shows twin pregnancies with TBA ≥100 μmol/L, and Fig. 1-D shows the dynamic fluctuation of all included twin pregnancies. Our data indicate that the peak TBA levels could dynamically change during the entire pregnancy and could quickly increase near term for various TBA levels, even with treatment. However, high TBA levels frequently recovered to normal between 1 and 5 weeks after birth.

A correlation analysis was performed using matched TBA levels from maternal serum, umbilical venous blood, and amniotic fluid samples from 33 twin pregnancies. Maternal TBA levels at their peak over the entire pregnancy (r = 0.61, P < 0.05) and upon birth (r = 0.76, P < 0.05) were positively correlated with the TBA levels in the amniotic fluid (Fig. 2-A). Similarly, maximum maternal TBA levels (r = 0.44, P < 0.05) and TBA levels at delivery (r = 0.47, P < 0.05) were positively correlated with TBA levels in the umbilical cord blood (Fig. 2-B). TBA levels in umbilical cord blood and amniotic fluid were similarly found to have a significant and positive correlation (r = 0.52, P < 0.05) (Fig. 2-C).

The Pearson parametric correlation test was performed to generate a correlation matrix using all maternal serum maximum TBA levels, TBA levels at delivery, and umbilical cord blood biochemical indicators of these 33 twin pregnancies (Fig. 3). Our findings revealed that umbilical cord blood TBA (r = 0.47, P < 0.05), CRE (r = 0.48, P < 0.05), Cl (r = 0.41, P < 0.05), and Mg (r = 0.39, P < 0.05) had a significant positive correlation with the maximum maternal serum TBA levels, whereas umbilical cord blood P (r = −0.47, P < 0.05) had a significant negative correlation with the maximum TBA levels. The TBA (r = 0.44, P < 0.05), Cl (r = 0.53, P < 0.05), TB (r = 0.36, P < 0.05), GLB (r = 0.27, P < 0.05), and ALB (r = 0.27, P < 0.05) levels in umbilical cord blood had a significant positive correlation with maternal serum TBA levels at delivery. A significant negative association was observed between P (r = −0.53, P < 0.05) in umbilical cord blood and serum TBA levels at delivery.

**Discussion**

Twin pregnancies with ICP had a higher risk of CS, PTB, fetal distress, and NICU admission than singleton pregnancies with ICP. Higher TBA levels were linked to a
higher risk of these adverse perinatal outcomes. Furthermore, we discovered a significant positive correlation between maternal serum, amniotic fluid, and umbilical cord blood TBA levels. Similarly, maternal TBA levels were significantly correlated with umbilical cord blood TBA, TB, GLB, ALB, CRE, Cl, and Mg.

Elderly maternal age, a family history of ICP, ICP in a previous pregnancy, and multiple pregnancies have been linked to an elevated risk of ICP [10, 24, 25]. ART, such as IVF-ET and/or ICSI, is associated with an increased risk of PPROM and ICP in twin pregnancies [5, 26]. Similarly, in our study, we discovered that the incidence of a history of ICP and IVF-ET was higher in twin pregnancies than in singleton pregnancies with ICP.

ICP is associated with increased rates of adverse perinatal outcomes [27, 28]. The rates of perinatal mortality, MSAF, fetal distress, and spontaneous PTB were found to be 3.5-11%, 27-45%, 14-22%, and 30-44% in ICP, respectively [29]. Effective fetal surveillance that can lower the risk of adverse fetal outcomes is currently lacking, and few studies have examined twin pregnancy and ICP. In our research, we discovered that twin pregnancies with ICP had a greater rate of CS, PTB, fetal distress, and NICU admission than singleton pregnancies with ICP, implying that ICP is more severe in twin pregnancies than in singletons.

The most lethal adverse perinatal complication of ICP is sudden stillbirth [30]. Stillbirth risk was higher in all cases of ICP [9], especially in those with peak serum TBA ≥ 100 μmol/L [28]. Elevated TBA could cause vasoconstriction disorders in the placental chorionic vessels and umbilical vein [5, 8, 10], which could be a factor in the increased risk of fetal distress, asphyxia, and sudden stillbirth in ICP [3, 5, 31]. ICP with TBA ≥ 100 μmol/L causes

---

Table 3: The subgroup analysis of perinatal outcomes of twin pregnancy of ICP with TBA ≥ 10 umol/L

| Indicator | TBA (10-40) | TBA (40-100) | TBA ≥ 100 | p     |
|-----------|-------------|--------------|-----------|-------|
| CS, n (%) | 449 (97.8)  | 129 (91.5)   | 17 (94.4) | < 0.05*|
| VD, n (%) | 10 (2.2)    | 12 (8.5)     | 1 (5.6)   | < 0.05*|
| PTB, n (%)| 364 (79.3)  | 129 (91.4)   | 36 (100.0)| < 0.05*|
| Gestational age [week], median (IQR) | 36 (34, 36) | 35 (34, 36) | 34 (33, 35) | < 0.05*|
| neonatal outcomes | | | | |
| Stillbirth, n (%) | 1 (0.1) | 4 (1.4) | 0 (0.0) | < 0.05*|
| Fetal distress, n (%) | 17 (1.9) | 4 (1.4) | 4 (11.1) | < 0.05*|
| Neonatal asphyxia, n (%) | 10 (1.1) | 7 (2.5) | 2 (5.6) | < 0.05*|
| Neonatal death, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | Na |
| NICU, n (%) | 207 (22.6) | 73 (26.3) | 12 (33.3) | 0.17 |
| MSAF, level, n (%) | | | | < 0.05*|
| No | 824 (90.1) | 215 (77.9) | 23 (63.9) |
| Type I (yellow) | 57 (6.2) | 30 (10.9) | 1 (2.8) |
| Type II (green) | 18 (2.0) | 11 (4.0) | 7 (19.4) |
| Type III (thick) | 16 (1.7) | 20 (7.2) | 5 (13.9) |
| Birth height (cm), median (IQR) | 46 (44, 47) | 45 (43, 47) | 43 (42, 45) | < 0.05*|
| Birth weight (g), median (IQR) | 2300 (2040, 2550) | 2240 (1965, 2460) | 1980 (1747, 2122) | < 0.05*|
| Birth weight (g), level, n (%) | | | | < 0.05*|
| < 2500 | 633 (69.3) | 218 (78.1) | 34 (94.4) |
| [2500-4000] | 280 (30.7) | 61 (21.9) | 2 (5.6) |
| > 4000 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Gestational age [week], level, n (%) | | | | < 0.05*|
| [0,28) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| [28,32) | 38 (4.1) | 16 (5.7) | 0 (0.0) |
| [32,34) | 78 (8.5) | 37 (13.2) | 12 (33.3) |
| [34,35) | 116 (12.6) | 34 (12.1) | 10 (27.8) |
| [35,36) | 206 (22.4) | 96 (34.2) | 14 (38.9) |
| [36,37) | 290 (31.6) | 74 (26.3) | 0 (0.0) |
| [37, Inf) | 190 (20.7) | 24 (8.5) | 0 (0.0) |

ICP: intrahepatic cholestasis of pregnancy, TBA: total bile acid, CS: Cesarean section, VD: Vaginal delivery, PTB: Preterm birth, NICU: Neonatal Intensive Care Unit, MSAF: Meconium-stained amniotic fluid.
6.8% of prenatal deaths [32]. Most stillbirths of singletons with ICP occur after 37 weeks of pregnancy [33], whereas stillbirths occur at an earlier gestational age in twin pregnancies with ICP. Stillbirth occurs in approximately 3.9% of twin pregnancies with ICP, according to Liu et al. [34]. In our study, the rate of stillbirth in twin pregnancies with ICP was 0.4% (5/633). Our hospital’s aggressive perinatal care management strategies, which were implemented to prevent stillbirth, are responsible for the reduced incidence of stillbirth in twin pregnancies with ICP.

The main concern of ICP management is stillbirth. The perinatal management of twin pregnancies with ICP is challenging for the obstetrician. Given the higher risk of fetal death, different guidelines recommend active management, such as enhanced monitoring and early delivery, to reduce the risk of fetal complications [5], which in turn increases the incidence of iatrogenic PTB [28]. The increased rate of iatrogenic PTB, especially in twin pregnancies, may be due to the active management of ICP. Similarly, our findings corroborated similar conclusions. We discovered that the rate of stillbirth was 0.4% in twin pregnancies with ICP, while the rate of PTB was 82.6%.

In twin pregnancies, ICP is a risk factor for PTB. However, the optimal time of delivery for women with twin pregnancies and ICP has not yet been determined. The reduction in stillbirths needs to be balanced with with the morbidities of prematurity and other perinatal problems.

Fig. 1 Dynamic TBA variation in twin pregnancies with ICP at various TBA levels. A Twin pregnancies with 10 ≤ TBA < 40 μmol/L. B Twin pregnancies with 40 ≤ TBA < 100 μmol/L. C Twin pregnancies with TBA ≥ 100 μmol/L. D All included twin pregnancies. Three different colored lines are used to depict the dynamic fluctuation of TBA in twin pregnancies with ICP during pregnancy and 5 weeks after delivery. The red line represents the maximum levels of TBA of included patients, the blue line represents the mean levels of TBA of included patients, and the yellow line represents the minimum levels of TBA of included patients.
Based on our center’s experience, close antenatal monitoring and active and individual perinatal management are needed. Moreover, the timing of delivery should be discussed on an individual basis according to the known perinatal risk and benefits of available management options.

Our findings also suggest that peak TBA levels may fluctuate throughout pregnancy and may rise rapidly near term, even with medication therapy. Maximum TBA levels were linked to an increased risk of stillbirth in both drug-treated and untreated ICP [28]. Hence, the close and regular monitoring of serum TBA levels is essential; additionally, once ICP is diagnosed, repeating the TBA test until delivery is recommended to help guide the perinatal management of ICP, particularly in severe cases such as twin pregnancies with ICP.

In ICP, UDCA has been shown to relieve maternal pruritus, lower serum TBA levels, and improve liver function [10, 24, 35]. UDCA treatment was provided to all study participants in our study. Furthermore, we discovered that high TBA levels reverted to normal levels almost 1 to 5 weeks after birth and that liver function returned to normal 4 to 6 weeks thereafter.

Brouwers, L. et al. [22] discovered a positive correlation between maternal serum TBA levels at diagnosis and delivery and umbilical cord blood TBA levels, indicating that TBA can be transported across the placenta. Similarly, we explored the correlations between maternal serum, umbilical cord blood, and amniotic fluid TBA levels in twin pregnancies with ICP. Our findings revealed a strong positive correlation between maternal serum, amniotic fluid, and umbilical cord blood TBA levels. TBA levels in maternal serum, umbilical cord blood, and amniotic fluid have all been found to be higher, which could be

**Fig. 2** TBA levels in maternal serum, umbilical venous blood, and amniotic fluid with Pearson correlation scatterplots. A The ordinate of Fig. 2-A represents TBA levels in the amniotic fluid, Fig. 2-A1 the maximum serum TBA levels ($r = 0.61, P < 0.05$), and Fig. 2-A2 the TBA levels upon delivery ($r = 0.76, P < 0.05$). B The ordinate of Fig. 2-B shows TBA levels in the umbilical venous blood, Fig. 2-B1 shows the maximum serum TBA levels ($r = 0.44, P < 0.05$), and Fig. 2-B2 shows TBA levels at delivery ($r = 0.47, P < 0.05$). C The correlation of TBA levels in umbilical venous blood and amniotic fluid ($r = 0.52, P < 0.05$) is shown in Fig. 2-C. Significant correlations have a $P$ value of less than 0.05.
due to maternal-fetal circulation. As a result, we hypothesize that TBA is transported through the placenta and is involved in the utero-placental-fetal circulation.

Changes in bile salt and electrolyte transport processes, as well as lipid structure, may be involved in the etiology of ICP, according to Reyes H, et al. [36]. However, the linked etiological mechanism has not been investigated since then. TBA, TB, ALB, GLB, CRE, Cl, and Mg levels in umbilical cord blood had a strong positive correlation with maternal serum TBA levels in our study. This finding may provide some scientific evidence and direction for the etiological mechanism study of bile salt and electrolyte transport pathways in ICP.

An advantage of the current study is that it was one of the largest cohort studies in China focusing on the effect of different categories of TBA levels on the perinatal outcomes of twin pregnancies with ICP. This cohort was studied using the modern active management strategy, as well as dynamic and continuous testing of liver function and TBA levels during pregnancy. Second, we were the first to investigate the link between maternal serum, umbilical cord blood, and amniotic fluid. Finally, we are the first to investigate the link between maternal
serum TBA levels and umbilical cord blood electrolyte and bilirubin levels. Our findings point to new directions for research and a better understanding of the etiological mechanisms of bile salt and electrolyte transport pathways in ICP. However, because this work was a single-center retrospective study, it has limitations. A large-scale, multicenter cohort study is necessary in the future to investigate alternative diagnostic and therapeutic interventions in ICP.

Conclusions
In conclusion, twin pregnancies with ICP in our study had a higher risk of CS, PTB, fetal distress, and NICU admission than singleton pregnancies with ICP, which was related to higher TBA levels. TBA is involved in uterine-placenta-fetal circulation and can be transferred through the placenta.

Abbreviations
ICP: Intrahepatic cholestasis of pregnancy; TBA: Total bile acid; CS: Cesarean section; PTB: Preterm birth; NICU: Neonatal intensive care unit; MSAF: Meconium-stained amniotic fluid; RDS: Respiratory distress syndrome; ALT: Aspartate aminotransferase; AST: Asparagine aminotransferase; IVF-ET: In vitro fertilization and embryo transfer; VD: Vaginal delivery; DBIL: Direct bilirubin; IDIL: Indirect bilirubin; GGT: γ-glutamyltransferase; ALB: Albumin; GLB: Globulin; A/G: Albumin/Globulin; A1: Apolipoproteins A1; apo B: Apolipoproteins B; HCY: Homocysteine; Na: Sodium; P: Phosphorus; Mg: Magnesium; K: Kalium; Cl: Chlorine; Ca: Calcium; NST: Nonstress test; IVH: Intraventricular hemorrhage; MCMA: Monochorionic monoamniotic; MCDA: Monochorionic diamniotic; DCDA: Dichorionic diamniotic.

Acknowledgments
We would like to thank the clinical staff at the Department of Obstetrics who helped us collect clinical data. All persons that contributed to this study are listed as authors and meet the criteria for authorship.

Authors’ contributions
TTX, HY, and XDW conceived the study. CYD, YCZ, QH, and GQH interpreted the data and literature review. TTX, XW, and BG analyzed the data. TTX drafted the manuscript. HY and XDW revised the manuscript and supervised the whole study. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 81571446), the National Natural Science Foundation for Young Scientists of China (Grant No. 82001560), and the Science Foundation of Chengdu University (No. 2021-YF05-01532-SN).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the ethical committees at the West China Second University Hospital of Sichuan University. All methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from patients before the procedure and manuscript publication.

Consent for publication
Not Applicable.

Competing interests
The authors have no actual or potential conflicts of interest to declare. All the funding bodies took part in the design of the study and collection, analysis, and interpretation of data, and the writing of the manuscript.

Author details
1 Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China. 2 Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University) Ministry of Education, Chengdu 610041, Sichuan, China. 3 West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.

Received: 20 June 2022 Accepted: 26 October 2022
Published online: 05 November 2022

References
1. Sharma AV, John S. Liver disease in pregnancy. In: StatPearls: StatPearls Publishing, 2019.
2. Bacq Y. Liver diseases unique to pregnancy: a 2010 update. Clin Res Hepatol Gastroenterol. 2011;35(3):182–93.
3. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2014;124(1):120–33.
4. Berg B, Helm G, Petersohn L, Tryding N. Cholestasis of pregnancy. Clinical and laboratory studies. Acta Obstet Gynecol Scand. 1986;65(2):107–13.
5. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol. 2009;15(17):2049–66.
6. Florenani A, Gervasi MT. New insights on intrahepatic cholestasis of pregnancy. Clin Liver Dis. 2016;20(1):177–89.
7. Batry L, Zloto K, Kalter A, Baum M, Mazaki-Tovi S, Yinon Y. Perinatal outcomes of intrahepatic cholestasis of pregnancy in twin versus singleton pregnancies: is plurality associated with adverse outcomes? Arch Gynecol Obstet. 2019;300(4):881–7.
8. Mei Y, Gao L, Lin Y, Luo D, Zhou X, He L. Predictors of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy with dichorionic diamniotic twin pregnancies. J Matern Fetal Neonatal Med. 2019;32(3):472–6.
9. Puljic A, Kim E, Page J, Esakoff T, Shaffer B, LaCoursiere DY, et al. The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age. Am J Obstet Gynecol. 2015;212(5):667.e661–5.
10. Ozkan S, Ceylan Y, Ozkan OV, Yildirim S. Review of a challenging clinical issue: intrahepatic cholestasis of pregnancy by gestational age. Am J Obstet Gynecol. 2015;212(3):713–41.
11. Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis 2011.
12. Gao XX, Ye MY, Liu Y, Li JY, Li L, Chen W, et al. Prevalence and risk factors of intrahepatic cholestasis of pregnancy in a Chinese population. Sci Rep. 2020;10(1):16307.
13. Li L, Chen W, Ma L, Liu ZB, Lu X, Gao XX, et al. Continuous association of total bile acid levels with the risk of small for gestational age infants. Sci Rep. 2020;10(1):9257.
14. Reyes H. What have we learned about intrahepatic cholestasis of pregnancy? Hepatology. 2016;63(1):1–4.
15. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology. 2014;59(4):1482–91.
16. Wang XD, Yao Q, Peng B, Zhang L, Ai Y, Ying YJ, et al. A clinical of intrahepatic cholestasis of pregnancy in 1241 cases (in Chinese). Chin J Hepatol. 2007;15(4):291–3.
17. Shen D, Hu Y, Qiu P, Mathew BS, Chen Y, Li S, et al. Intrahepatic cholestasis of pregnancy in women with twin pregnancy. Twin Res Hum Genet. 2011;16(6):697–707.
18. Guidelines of the Chinese Medical Association of obstetrics and gynecology. Chin J Obstet Gynecol2015;31(7):481-5.
19. Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol. 2018;231:180–7.
20. Rodríguez Fernández V, Ramón YCCNL, Ortiz EM, Naveira EC. Intrapartum and perinatal results associated with different degrees of staining of meconium-stained amniotic fluid. Eur J Obstet Gynecol Reprod Biol. 2018;224:192–7.
21. Mei Y, Lin Y, Luo D, Gao L, He L. Perinatal outcomes in intrahepatic cholestasis of pregnancy with monochorionic diamniotic twin pregnancy. BMC pregnancy and childbirth. 2018;18(1):291.
22. Brouwers L, Koster MP, Page-Christiaans GC, Kemperman H, Boon J, Even IM, et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol. 2015;212(1):100.e101–7.
23. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004;40(2):467–74.
24. Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, et al. Unsaturated bile acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019;394(10201):849–60.

25. Arrese M, Reyes H. Intrahepatic cholestasis of pregnancy: a past and present riddle. Ann Hepatol. 2006;5(3):202–5.
26. Sun L, Zou G, Wei X, Chen Y, Zhang J, Okun N, et al. Clinical outcomes after assisted reproductive technology in twin pregnancies: chorionicity-based comparison. Sci Rep. 2016;6:26869.
27. Lee RH, Mara G, Metz TD, Pettiker CM. Society for Maternal-Fetal Medicine Consult Series #53: intrahepatic cholestasis of pregnancy: replaces consult #13, April 2011. Am J Obstet Gynecol. 2021;224(2):82–b9.
28. Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393(10174):899–909.
29. Diken Z, Usta IM, Nassar AH. A clinical approach to intrahepatic cholestasis of pregnancy. Am J Perinatol. 2014;31(1):1–8.
30. Arthur C, Mahomed K. Intrahepatic cholestasis of pregnancy: diagnosis and management; a survey of Royal Australian and New Zealand College of Obstetrics and Gynaecology fellows. Aust N Z J Obstet Gynaecol. 2014;54(3):263–7.
31. Sepulveda WH, Gonzalez C, Cruz MA, Rudolph MI. Vasoconstrictive effect of bile acids on isolated human placental chorionic veins. Eur J Obstet Gynecol Reprod Biol. 1991;42(3):211–5.
32. Di Mascio D, Quist-Nelson J, Riegel M, George B, Saccone G, Brun R, et al. Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review. J Matern Fetal Neonatal Med. 2021;34(21):3614–22.
33. Williamson C, Hems LM, Goullas DG, Walker I, Chambers J, Donaldson O, et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG. 2004;111(7):676–81.
34. Liu X, Landon MB, Chen Y, Cheng W. Perinatal outcomes with intrahepatic cholestasis of pregnancy in twin pregnancies. J Matern Fetal Neonatal Med. 2016;29(13):2176–81.
35. Vasavan T, Deepak S, Jayawardane IA, Lucchini M, Martin C, Geenes V, et al. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations. J Hepatol. 2021;74(5):1087–96.
36. Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: an estrogen-related disease. Semin Liver Dis. 1993;13(3):289–301.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.